The failure of clinical trials can stem from multiple factors. One study suggests that 90% of drug development clinical failures may be attributed to four reasons: lack of clinical efficacy (40%-50%), uncontrollable toxicity (30%), poor pharmacokinetic properties (10%-15%), and absence of commercial demand or poor strategic planning (10%).
Mabwell has declared that its fully-owned subsidiary, T-mab, has successfully received the green light for its Denosumab Injection from the National Medical Products Administration.
As the potential of molecular glue technology becomes increasingly apparent, pharmaceutical companies are beginning to invest more heavily in this area.
April 11th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
April 10th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
April 9th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Bitopic ligands of GPCRs (G protein-coupled receptors) refer to a single chemical entity composed of two pharmacophoric groups covalently linked together.